This document is an excerpt from the EUR-Lex website
Document 52025M11592
Prior notification of a concentration (Case M.11592 – ROQUETTE / IFF PHARMA SOLUTIONS BUSINESS)
Prior notification of a concentration (Case M.11592 – ROQUETTE / IFF PHARMA SOLUTIONS BUSINESS)
Prior notification of a concentration (Case M.11592 – ROQUETTE / IFF PHARMA SOLUTIONS BUSINESS)
PUB/2025/62
OJ C, C/2025/598, 23.1.2025, ELI: http://data.europa.eu/eli/C/2025/598/oj (BG, ES, CS, DA, DE, ET, EL, EN, FR, GA, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
Official Journal |
EN C series |
|
C/2025/598 |
23.1.2025 |
Prior notification of a concentration
(Case M.11592 – ROQUETTE / IFF PHARMA SOLUTIONS BUSINESS)
(Text with EEA relevance)
(C/2025/598)
1.
On 14 January 2025, the Commission received notification of a proposed concentration pursuant to Article 4 and following a referral pursuant to Article 4(5) of Council Regulation (EC) No 139/2004 (1).This notification concerns the following undertakings:
|
— |
Roquette Frères S.A. (‘Roquette’, France), |
|
— |
The Pharma Solutions Business and some product lines of the Nourish Business (the ‘Target Business’) of International Flavors and Fragances Inc. (‘IFF’, United States). |
Roquette will acquire within the meaning of Article 3(1)(b) of the Merger Regulation sole control of the whole of the Target Business from IFF.
The concentration is accomplished by way of purchase of shares.
2.
The business activities of the undertakings concerned are the following:|
— |
Roquette is active in the production and sale of plant-based ingredients, excipients, and plant proteins for various applications, |
|
— |
The Target Business focuses mainly on the production and sale of a range of cellulosics and other types of plant-based pharmaceutical excipients. |
3.
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.
4.
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.11592 – ROQUETTE / IFF PHARMA SOLUTIONS BUSINESS
Observations can be sent to the Commission by email or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Postal address:
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
1049 Bruxelles/Brussel |
|
BELGIQUE/BELGIË |
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).
ELI: http://data.europa.eu/eli/C/2025/598/oj
ISSN 1977-091X (electronic edition)